- Home
- RMTI vs CGTX Comparison
RMTI vs CGTX Comparison
Compare RMTI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMTI | CGTX |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 158.8M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RMTI | CGTX |
|---|---|---|
| Price | $0.92 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $2.88 |
| AVG Volume (30 Days) | 227.0K | ★ 942.9K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,577,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $0.22 |
| 52 Week High | $2.41 | $3.83 |
Technical Indicators
Market Signals| Indicator | RMTI | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.56 | 53.10 |
| Support Level | $0.87 | $1.69 |
| Resistance Level | $0.97 | $1.77 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 34.62 | 75.58 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.